{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1240","upperLimit":"2560","value":"1850"},{"groupId":"OG001","lowerLimit":"2870","upperLimit":"4240","value":"3450"},{"groupId":"OG002","lowerLimit":"3910","upperLimit":"4950","value":"4520"},{"groupId":"OG003","lowerLimit":"2750","upperLimit":"7570","value":"5260"},{"groupId":"OG004","lowerLimit":"1590","upperLimit":"4970","value":"3710"},{"groupId":"OG005","lowerLimit":"9040","upperLimit":"14300","value":"10400"},{"groupId":"OG006","lowerLimit":"7060","upperLimit":"14000","value":"10500"},{"groupId":"OG007","lowerLimit":"5620","upperLimit":"14000","value":"9690"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"AUC(3weeks): AMG 224 Conjugated Antibody after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1340","upperLimit":"2900","value":"2330"},{"groupId":"OG001","lowerLimit":"3460","upperLimit":"3840","value":"3650"},{"groupId":"OG002","lowerLimit":"5820","upperLimit":"7250","value":"6360"},{"groupId":"OG003","lowerLimit":"4000","upperLimit":"9640","value":"7400"},{"groupId":"OG004","lowerLimit":"4250","upperLimit":"12400","value":"7610"},{"groupId":"OG005","lowerLimit":"13100","upperLimit":"15100","value":"14100"},{"groupId":"OG006","lowerLimit":"23000","upperLimit":"23000","value":"23000"},{"groupId":"OG007","lowerLimit":"10100","upperLimit":"20800","value":"15500"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"7"}],"units":"Participants"}],"title":"AUC(3weeks): AMG 224 Conjugated Antibody after Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1300","upperLimit":"2690","value":"1990"},{"groupId":"OG001","lowerLimit":"3300","upperLimit":"4450","value":"3850"},{"groupId":"OG002","lowerLimit":"4540","upperLimit":"5910","value":"5120"},{"groupId":"OG003","lowerLimit":"3160","upperLimit":"8110","value":"5870"},{"groupId":"OG004","lowerLimit":"2200","upperLimit":"5440","value":"4220"},{"groupId":"OG005","lowerLimit":"10400","upperLimit":"12500","value":"11300"},{"groupId":"OG006","lowerLimit":"6140","upperLimit":"16200","value":"11200"},{"groupId":"OG007","lowerLimit":"6640","upperLimit":"11400","value":"8680"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"AUC(3weeks): Total Anti-BCMA Antibody after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1460","upperLimit":"3310","value":"2530"},{"groupId":"OG001","lowerLimit":"4180","upperLimit":"4560","value":"4370"},{"groupId":"OG002","lowerLimit":"7140","upperLimit":"10100","value":"8140"},{"groupId":"OG003","lowerLimit":"4660","upperLimit":"13200","value":"9170"},{"groupId":"OG004","lowerLimit":"4900","upperLimit":"16100","value":"9250"},{"groupId":"OG005","lowerLimit":"17400","upperLimit":"20500","value":"18500"},{"groupId":"OG006","lowerLimit":"24700","upperLimit":"24700","value":"24700"},{"groupId":"OG007","lowerLimit":"8880","upperLimit":"18600","value":"13000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"7"}],"units":"Participants"}],"title":"AUC(3weeks): Total Anti-BCMA Antibody after Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"0.0729","upperLimit":"0.0729","value":"0.0729"},{"groupId":"OG005","lowerLimit":"0.0328","upperLimit":"0.0597","value":"0.0487"},{"groupId":"OG006","lowerLimit":"0.0421","upperLimit":"0.0668","value":"0.0579"},{"groupId":"OG007","lowerLimit":"0.0426","upperLimit":"0.0743","value":"0.0646"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"title":"AUC(0-96hr): DM1 after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"0.0561","upperLimit":"0.0561","value":"0.0561"},{"groupId":"OG005","lowerLimit":"0.0484","upperLimit":"0.0770","value":"0.0654"},{"groupId":"OG006","lowerLimit":"0.0684","upperLimit":"0.0684","value":"0.0684"},{"groupId":"OG007","lowerLimit":"0.0588","upperLimit":"0.0865","value":"0.0688"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"7"}],"units":"Participants"}],"title":"AUC(0-96hr): DM1 after Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"description":"AUC from time zero to 3 weeks (AUC(3 weeks)) was determined for AMG 224 conjugated antibody and total anti-BCMA antibody, and AUC from time zero to 96 hours (AUC(0-96hr)) was determined for DM1.","dispersionType":"Full Range","groups":[{"description":"Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG000","title":"Dose Exploration: AMG 224 Dose A"},{"description":"Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG001","title":"Dose Exploration: AMG 224 Dose B"},{"description":"Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG002","title":"Dose Exploration: AMG 224 Dose C"},{"description":"Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG003","title":"Dose Exploration: AMG 224 Dose D"},{"description":"Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG004","title":"Dose Exploration: AMG 224 Dose E"},{"description":"Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG005","title":"Dose Exploration: AMG 224 Dose F"},{"description":"Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG006","title":"Dose Exploration: AMG 224 Dose G"},{"description":"All participants in Dose Expansion who had prior treatment or no prior treatment with a CD38-targeting antibody were administered the MTD of AMG 224 identified in the dose escalation as 3 mg/kg. AMG 224 was administered as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG007","title":"Dose Expansion: AMG 224 3 mg/kg"}],"paramType":"MEAN","populationDescription":"The PK parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated. All participants included in the overall number of participants analyzed contributed data to this endpoint.","reportingStatus":"POSTED","timeFrame":"AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycle 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)","title":"Area Under the Concentration-time Curve (AUC) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1","type":"SECONDARY","unitOfMeasure":"h*µg/mL"}